Test Price
2,800 AED✅ Home Collection Available
CDH3 Gene Ectodermal Dysplasia, Ectrodactyly, and Macular Dystrophy Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين CDH3 لخلل التنسج الأديمي الظاهر، وانعدام الأصابع، والحثل البقعي في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
الملخص التنفيذي
اختبار جين CDH3 بتقنية التسلسل الجيني من الجيل التالي (NGS) في مختبرنا المعتمد آيزو 9001:2015 بدولة الإمارات، يضمن دقة تشخيصية تصل إلى 99.9%، مع خدمة سحب منزلي على مستوى المستشفيات بنقل مبرد معزول، وإرشاد سريري هاتفي بعد النتيجة، وإمكانية التحقق المباشر من تغطية التأمين عبر واتساب.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Transport and VIP Mobile Phlebotomy
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in Result Interpretation
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
Comprehensive Overview
The CDH3 gene test uses Next‑Generation Sequencing to analyze all coding regions of the P‑cadherin gene, confirming or excluding ectodermal dysplasia, ectrodactyly, and macular dystrophy (EEM) syndrome. يقدم هذا الفحص الجيني الشامل تشخيصًا دقيقًا يساعد أطباء الجلدية والوراثة وعلم الأورام في الإمارات على وضع خطة علاجية ملائمة.
Why Our Test Outperforms Standard Alternative
| Feature | Our NGS Test | Conventional Sanger Sequencing |
|---|---|---|
| Diagnostic Sensitivity | 99.9% for all coding exons & splice sites | ~95%, limited to targeted variant/region |
| Methodology | Massively parallel NGS (ISO-15189 calibrated) | Single‑region chain‑termination method |
| Turnaround Time | 3–4 weeks | 5–6 weeks |
| Variant Detection | Single nucleotide, small indels, copy number variants* | Only known point mutations in targeted amplicon |
*CNV detection via validated bioinformatics pipeline.
Physician Insight & Safety Protocol
“As a board‑certified dermatologist, I encourage every patient to understand that genetic test outcomes must be integrated with a thorough physical examination and detailed family history; a positive result provides molecular confirmation of EEM syndrome, while a negative result does not rule out all genetic causes. Please discuss the findings with your treating physician before making any health‑related decision.” – Dr. Prabhakar Reddy, DHA License 61713011.
⚠ Medication Warning:
Do not discontinue prescribed medication without consulting your doctor.
Exclusion Criteria & ER Red Flags
- Exclusion Criteria: Individuals with acute febrile illness or recent blood transfusion (within 14 days) should postpone collection; pregnant women must consult obstetrician before testing.
- ER Red Flags: If you experience sudden vision loss, severe skin blistering with fever, or acute limb deformity, seek emergency care immediately – these are not related to routine phlebotomy but may indicate underlying disease progression requiring urgent intervention.
Patient FAQ & Clinical Guidance
Q1: What is the CDH3 gene test and what conditions does it diagnose?
Quick Answer: The CDH3 gene test detects mutations in the P‑cadherin gene responsible for ectodermal dysplasia, ectrodactyly, and macular dystrophy (EEM) syndrome.
This test sequences the entire coding region to identify pathogenic variants, helping dermatologists and clinical geneticists confirm the diagnosis and guide multidisciplinary management. It is particularly indicated for individuals with abnormal skin, nail, hair development, missing fingers/toes, and retinal changes.
السؤال بالعربية
ما هو اختبار جين CDH3 وما هي الحالات التي يشخصها؟
جواب سريع: يكشف اختبار جين CDH3 عن الطفرات في جين P‑cadherin المسببة لمتلازمة خلل التنسج الأديمي الظاهر وانعدام الأصابع والحثل البقعي (EEM).
Q2: Why is this NGS preferred for suspected ectodermal dysplasia syndrome?
Quick Answer: Next‑generation sequencing offers near‑exhaustive coverage of all CDH3 coding exons with superior sensitivity compared to older single‑gene methods.
NGS can simultaneously identify point mutations, small insertions/deletions, and even copy number changes, reducing the time to a definitive answer for families seeking clarity. Coupled with our ISO‑certified workflow, the accuracy of 99.9% ensures you receive results that are both clinically actionable and reliable for genetic counseling.
السؤال بالعربية
لماذا يُفضَّل اختبار التسلسل الجيني (NGS) لمتلازمة خلل التنسج الأديمي الظاهر المُشتبهة؟
جواب سريع: تُتيح تقنية التسلسل من الجيل التالي تغطية شاملة لكل الإكسونات المشفرة لجين CDH3 بحساسية تفوق الطرق التقليدية بكثير.
Q3: How is the sample collected and what preparation is required?
Quick Answer: A simple blood draw or DNA sample on an FTA card is collected, ideally after a genetic counselling session to document family pedigree.
Our home phlebotomy service visits between 8 AM and 11 PM, ensuring minimal disruption. No fasting is required; however, we advise avoiding strenuous exercise 24 hours before collection to maintain sample integrity. The specimen is immediately stored in a cold‑chain until ISO‑calibrated NGS processing.
السؤال بالعربية
كيف يتم جمع العينة وما التجهيزات المطلوبة؟
جواب سريع: تُسحب عينة دم بسيطة أو تُوضع قطرة دم على بطاقة FTA، ويفضل بعد جلسة استشارة وراثية لتوثيق شجرة العائلة.
This laboratory is accredited under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139). All services comply with Federal Decree‑Law No. 41 of 2024 (Article 87), CDS Law 2026 for minors, and UAE Personal Data Protection Law. Results are confidential and released only to authorized individuals. For scheduling or insurance queries, WhatsApp +971545488731.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians